BioSpace News Archive

TRACON Pharmaceuticals (NASDAQ:TCON), today announced that at the special meeting of stockholders, held November 6, 2019, stockholders voted to approve a proposal authorizing the Board of Directors of the Company to amend the Company’s certificate of incorporation to effect a reverse split of TRACON’s outstanding common shares.

Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today reported financial results for the third quarter ended September 30, 2019 and provided an overview of the company’s recent progress.

A new study of 443 patients by Exact Sciences Corp. and its collaborators demonstrated 80% sensitivity at 90% specificity with a novel combination of six blood-based biomarkers for the most common type of liver cancer, hepatocellular carcinoma (HCC)i

Cirius Therapeutics, a clinical-stage pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and metabolic diseases, today announced data from its recently completed 12-month Phase 2b EMMINENCE clinical trial of MSDC-0602K for the treatment of non-alcoholic steatohepatitis (NASH).

Theranica Bio-Electronics Ltd., a bio-medical technology company developing advanced electroceuticals for migraine and other pain disorders, announced today that the American Headache Society published an article in its peer-reviewed journal, Headache: The Journal of Head and Face Pain,

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors declared a quarterly cash dividend of $0.19 per share.

Magellan Rx Management, LLC, a division of Magellan Health, Inc. (NASDAQ: MGLN), today announced it was accredited by the National Committee for Quality Assurance (NCQA) for Utilization Management.

Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that medical device executive Kelly U. Petrucci has been named Vice President of Healthcare Economics and Market Access.

Horizon Discovery Group plc announces an agreement to divest the Group’s animal research models business unit to Envigo RMS LLC (“Envigo”).

Mallinckrodt plc, a global biopharmaceutical company, will present at the Jefferies London Healthcare Conference in London on Wednesday, Nov. 20, 2019..